Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.

Saved in:
Bibliographic Details
Title: Ex vivo drug screening and clustering of bladder cancers for pre-clinical treatment prediction.
Authors: Conroy S; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Gagg H; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Quayle LA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; School of Computing and Digital Technologies, Sheffield Hallam University, Sheffield, UK., Adams JA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Williams ST; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Helleday T; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden., Hussain SA; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Griffin J; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Department of Histopathology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Allen R; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK., Rantala JK; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.; Misvik Biology Ltd, Karjakatu, Turku, Finland., Danson SJ; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. s.danson@sheffield.ac.uk.; Department of Oncology, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. s.danson@sheffield.ac.uk., Catto J; Department of Urology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. j.catto@sheffield.ac.uk.; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. j.catto@sheffield.ac.uk., Wells G; Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, UK. g.wells@sheffield.ac.uk.
Source: Communications medicine [Commun Med (Lond)] 2026 May 14. Date of Electronic Publication: 2026 May 14.
Publication Type: Journal Article
Journal Info: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond)
Database: MEDLINE Ultimate
Description
ISSN:2730-664X
DOI:10.1038/s43856-026-01596-5